Overview of the Current Market
The prevalence of multidrug-resistant (MDR) bacteria has increased in recent years as the development of novel antimicrobial agents has diminished. Drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp.(VRE), Pseudomonas aeruginosa, Acinetobacter baumannii and extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, present therapeutic challenges due to the limited number of antimicrobials with reliable activity. Furthermore, several investigations have concluded that the presence of drug-resistant pathogens can lead to ineffective empiric therapy, thereby contributing to poor patient outcomes. As a result, there is a growing need for the development of new antimicrobial agents with novel mechanisms of action and activity against drug-resistant pathogens. The addition of tigecycline to the current antimicrobial armamentarium will be helpful in meeting some of the challenges posed by bacterial resistance.
Expert Rev Anti Infect Ther. 2008;6(5):557-567. © 2008 Expert Reviews Ltd.
No writing assistance was utilized in the production of this manuscript.
Cite this: Establishing the Role of Tigecycline in an era of Antimicrobial Resistance - Medscape - Oct 01, 2008.